Annexon Highlights 2026 Milestones With Tanruprubart MAA Filing, Vonaprument Phase 3 Data In Dry AMD, ANX1502 Proof‑of‑Concept Readout, Snd Strong Cash Position Funding Into 2027
Benzinga Newsdesk 10 months ago
News
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026Vonaprument Pivotal Phase 3 Topline Data
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026
Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection
Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026
Strong Financial Position Funds Operations into Late 2027 Well Past Anticipated Key Milestones
BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today highlighted its 2026 strategic priorities and key milestones for its lead programs.